Manuscript no. HAEMATOL/2011/049593 entitled "Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity"

Authors: Shabnam H. Thathia, Stuart Ferguson, Hannah E. Gautrey, Sanne D. van Otterdijk, Michela Hili, Vikki Rand, Anthony V. Moorman, Stefan Meyer, Robert Brown and Gordon Strathdee

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Gordon Strathdee, Newcastle University, Gordon.Strathdee@ncl.ac.uk

   According to the International Committee of Medical Journal Editors (ICMJE) ([http://www.icmje.org/ethical_1author.html](http://www.icmje.org/ethical_1author.html)): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 ................. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study:
   • Robert Brown and Anthony Moorman were responsible for contributing to the concept of the project

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
   • Gordon Strathdee was contributed to the design of all experimental work
   • Shabnam H. Thathia, Stuart Ferguson, Hannah E. Gautrey and Sanne D. van Otterdijk were responsible for contributing to the design of specific experimental details within the project

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
   • Shabnam H. Thathia and Gordon Strathdee were responsible for the work described in Figure 1 and in Table 1
   • Stuart Ferguson and Michela Hili responsible for the work described in Figure 2
   • Shabnam H. Thathia was responsible for the work described in Figures 3 and 4 and supplementary figure 2
   • Hannah E. Gautrey and Sanne D. van Otterdijk were responsible for the work presented in supplementary table 1 and supplementary figure 1
   • Vikki Rand was responsible for comparison of the data with that in publically available gene expression data sets
   • Anthony Moorman and Robert Brown were responsible for interpretation of results and with statistical analysis
   • Stefan Meyer and Anthony Moorman were responsible for acquisition of patient material and for analysis of clinical data.
5) **Writing the manuscript.** The following authors were responsible for writing the manuscript:

- Gordon Strathdee had overall responsibility for drafting and editing of manuscript
- Shabnam H. Thathia, Stuart Ferguson, Hannah E. Gautrey, Sanne D. van Otterdijk and Michela Hili were responsible for writing or editing specific sections of manuscript relating to their contribution to acquisition of data, for critical review of manuscript and for approval of final version.
- Vikki Rand, Anthony V. Moorman, Stefan Meyer and Robert Brown were responsible for critical review of manuscript and for approval of final version.

6) **Contributors Listed in Acknowledgments:**

Profs A.G. Hall, A.M. Dickinson, D.G. Oscier and T.L. Hollyoake and the UK Cancer Cytogenetics Group (UKCCG) were acknowledged for providing data and samples and all clinicians involved in collection of leukaemia samples.

Funding for the study:

This work was supported by grants from the Newcastle Healthcare Charity (to G.S.), a Cancer Research UK programme grant (to R.B.) and from Leukaemia and Lymphoma Research (to A.V.M.) and a Cancer Research UK Clinician Scientist Fellowship (to SM).